AbbVie Inc. $ABBV Shares Acquired by Baker Avenue Asset Management LP

Baker Avenue Asset Management LP raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,687 shares of the company’s stock after buying an additional 4,305 shares during the quarter. Baker Avenue Asset Management LP’s holdings in AbbVie were worth $25,397,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the second quarter worth $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at about $39,000. Finally, Bear Mountain Capital Inc. raised its stake in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ABBV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday. UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Finally, Bank of America raised their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Price Performance

Shares of AbbVie stock opened at $219.21 on Friday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The business’s fifty day moving average price is $225.60 and its two-hundred day moving average price is $217.22. The company has a market capitalization of $387.42 billion, a P/E ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.